30 results about "Simian Adenoviruses" patented technology

A method for providing an adenovirus from a serotype which does not grow efficiently in a desired cell line with the ability to grow in that cell line is described. The method involves replacing the left and right termini of the adenovirus with the corresponding termini from an adenovirus which grow efficiently in the desired cell line. At a minimum, the left terminus spans the 5′ inverted terminal repeat, the left terminus spans the E4 region and the 3′ inverted terminal repeat. The resulting chimeric adenovirus contains the internal regions spanning the genes encoding the penton, hexon and fiber from the serotype which does not grow efficiently in the desired cell. Also provided are vectors constructed from novel simian adenovirus sequences and proteins, host cells containing same, and uses thereof.

A method for providing an adenovirus from a serotype which does not grow efficiently in a desired cell line with the ability to grow in that cell line is described. The method involves replacing the left and right termini of the adenovirus with the corresponding termini from an adenovirus which grow efficiently in the desired cell line. At a minimum, the left terminus spans the (5′) inverted terminal repeat, the left terminus spans the E4 region and the (3′) inverted terminal repeat. The resulting chimeric adenovirus contains the internal regions spanning the genes encoding the penton, hexon and fiber from the serotype which does not grow efficiently in the desired cell. Also provided are vectors constructed from novel simian adenovirus sequences and proteins, host cells containing same, and uses thereof.

A method for providing an adenovirus from a serotype which does not grow efficiently in a desired cell line with the ability to grow in that cell line is described. The method involves replacing the left and right termini of the adenovirus with the corresponding termini from an adenovirus which grow efficiently in the desired cell line. At a minimum, the left terminus spans the (5′) inverted terminal repeat, the left terminus spans the E4 region and the (3′) inverted terminal repeat. The resulting chimeric adenovirus contains the internal regions spanning the genes encoding the penton, hexon and fiber from the serotype which does not grow efficiently in the desired cell. Also provided are vectors constructed from novel simian adenovirus sequences and proteins, host cells containing same, and uses thereof.

The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and / or polynucleotide. The invention also relates to the use of the isolated polynucleotides, the isolated polypeptides, the vector, the adenoviruses and / or the pharmaceutical composition for the therapy or prophylaxis of a disease.

A method of inducing a CD8+ T-cell response against a selected molecule by delivering the molecule via a recombinant simian adenovirus is provided. Also provided are methods of inducing interferon-alpha and interferon-beta by delivering a recombinant simian adenovirus to a subject. The methods of the invention are particularly well suited for prophylaxis and treatment of infections with human immunodeficiency virus and human papilloma virus, among others, and cancer therapy.

The present invention relates to methods and materials for recombinant adeno-associated virus production. More particularly, in some embodiments the invention contemplates the use of an adenovirus known as Simian Adenovirus 13 (SAdV-13) and Vero cells for production of recombinant adeno-associated virus (rAAV).

Simian adenoviral vectors are formulated with bioadhesives and excipients that maintain immunogenicity. They can be administered mucosally to provide effective prophylaxis and therapy.

The present invention relates to recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are novel simian adenoviruses having a low seroprevalence and high immunogenicity relative to other adenoviruses and vectors thereof. The invention also provides methods for production of the adenoviruses and for the treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).

The present invention relates to novel adenovirus strains with a high immunogenicity and no pre-existing immunity in the general human population. The lack of pre-existing immunity is due to novel hypervariable regions in the adenoviral capsid protein hexon. The novel adenovirus strains also have an improved capacity for reproduction. The present invention provides nucleotide and amino acid sequences of these novel adenovirus strains, as well as recombinant viruses, virus-like particles and vectors based on these strains. Further provided are pharmaceutical compositions and medical uses in the therapy or prophylaxis of a disease, and methods for producing an adenovirus or virus-like particles utilizing the novel sequences, recombinant viruses, virus-like particles and vectors.

The present invention relates to simian adenovirus nucleic acid and amino acid sequences, vectors containing them and uses thereof. In particular, the present invention relates to novel adenovirus strains with improved seropositivity. In one aspect, the invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fibrin, fragments thereof and polynucleotides encoding the same. Also provided are vectors comprising the isolated polynucleotides according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and pharmaceutical combinations comprising said vectors, adenoviruses, polypeptides and / or polynucleotides things. The present invention also relates to the use of isolated polynucleotides, isolated polypeptides, vectors, adenoviruses and / or pharmaceutical compositions for the treatment or prevention of diseases.

The invention relates to preparing and using recombinant expression vectors for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2. One expression vector contains the recombinant human adenovirus serotype26 genome, wherein the E1 and E3 regions are deleted, and the ORF6-Ad26 region is replaced by ORF6-Ad5, with an integrated expression cassette of SEQ ID NO:1, 2, or 3 (variant 1). Therein, SEQ ID NO:5 was a parental sequence of human adenovirus serotype 26.Another expression vector contains the recombinant simian adenovirus serotype25 genome, wherein the E1 and E3 regions are deleted, with an integrated expression cassette of SEQ ID NO:4, 2, or 3 (variant 2). Therein, SEQ ID NO:6 was a parental sequence of simian adenovirus serotype 25.Further, the recombinant human adenovirus serotype5 genome is disclosed, wherein the E1 and E3 regions are deleted, with an integrated expression cassette of SEQ ID NO:1, 2, or 3 (variant 3). Therein, SEQ ID NO:7 was a parental sequence of human adenovirus serotype 5.

The present invention relates to biotechnology. The claimed agents can be used for the prevention of SARS-CoV-2. A pharmaceutical formulation is created which contains a component (1) comprising an agent in the genomic form of a recombinant human adenovirus serotype (26) in which an expression cassette selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 is placed, and which further contains a component (2) comprising an agent in the genomic form of a recombinant human adenovirus serotype (5) in which an expression cassette selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 is placed. Furthermore, a pharmaceutical formulation is created which contains a component 1 comprising an agent in the genomic form of a recombinant human adenovirus serotype (26) in which an expression cassette selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 is placed, and which further contains a component (2) comprising an agent in the genomic form of a recombinant simian adenovirus serotype (25) in which an expression cassette selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 is placed, wherein an expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2 and SEQ ID NO: 3 is placed. Furthermore, a pharmaceutical formulation is created which contains component 1 comprising an agent in the genomic form of a recombinant simian adenovirus serotype (25) in which an expression cassette selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3 is placed, and which further contains component (2) comprising an agent in the genomic form of a recombinant human adenovirus serotype (5) in which an expression cassette selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3 is placed, wherein an expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 is placed.

Novel hexon isolated from simian adenovirus serotype 19 encoded in the polynucleotide defined as SEQ ID NO: 3, hepervariable region thereof, chimeric adenovirus comprising the same, and therapeutic use thereof provides a solution to the problem of safety and effective systemic treatment for developing gene therapeutic agents using adenovirus.

Replication competent simian adenoviral vectors are provided for the delivery of exogenous immunogens. Vectors of the invention demonstrate superior replication and expression of exogenous immunogens. They are useful as prophylactic and therapeutic vaccines as well as in gene therapy.